ClinicalTrials.gg
CompletedNCT03201354Updated Jun 28, 2017

Efficacy and Safety of the ExPRESS Implant Versus Deep Sclerectomy in Combined Surgery

An interventional study of Filtration surgery with Ex-PRESS and Non penetrating deep sclerectomy in Open Angle Glaucoma and Ocular Hypertension, sponsored by Institut Catala de Retina. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-28.

Sponsored by Institut Catala de Retina · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Glaucoma, Open-Angle with a site in Spain — 6 open to participants now, 9 under way, none of them phase 3. Glaucoma, Open-Angle · Spain.

Enrollment
21st of 35
98 · median 107
Started
2012
with 2 others
No phase
18 of 47
4 open now
Registered
14th of 47
by date
Lead sponsor
2 of 47
Institut Catala de Retina

Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, this one is the 21st largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2012, is one of 18 with no phase, and was the 14th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

6 of the 47 studies in Glaucoma, Open-Angle with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Glaucoma, Open-Angle with a site in Spain, or all of them as a file.
02

Study summary

The Ex-PRESS Glaucoma Filtration Device is a small, non-valved implant that was designed to lower intraocular pressure (IOP) by shunting aqueous humor from the anterior chamber into the subconjunctival space. The implant was developed in response to the need for more straightforward, standardized and safe surgical technique than standard filtration surgery. No iridectomy and no sclerectomy is needed if an Ex-PRESS device is implanted under a partial-thickness scleral flap. This may reduce surgical time and complications when compared to a standard trabeculectomy.

In some studies it has been found to be safe and effective with few complications, even in high-risk patients. No previous studies have compared filtration surgery with Ex-Press implant to deep sclerectomy.

Read the detailed description

Hypothesis:

In combined procedure (cataract and filtering surgery), the effect of Ex-PRESS device has similar efficacy reducing intraocular pressure than non penetrant deep sclerectomy and with good level of safety.

Objective:

To evaluate and compare the efficacy and safety at 12 months of the filtering surgery with the Ex-PRESS device with that of deep sclerectomy.

Methods:

Design: Multi-center, prospective, simple-blind, randomized study.

Primary variable:

  1. Intraocular pressure.

Secondary variables:

  1. Success rate at IOP \<18
  2. Frequency and type of complications
  3. Number of hypotensive drugs needed.

Sample size calculation: Accepting an alfa risk of 0.05 and a beta risk of 0.20 in a two-sided Student's T-test, 50 subjects are necessary in first group and 50 in the second to recognize as statistically significant a difference greater than or equal to 10% in IOP, with a common standard deviation of 17%. A drop-out rate of 8% has been anticipated. If no drop-out rate is considered, the number of needed subjects is 92 (46 per group).

If the drop out rate is more than 8%:

  1. If the recruitment period is open, another subjects will be included.
  2. If the recruitment period os close, the inclusion of another subject will be evaluated to maintain the statistic power of the study.

Method

-Single blinded. Each patient will be assigned to one of the two arms (Ex-PRESS or Deep sclerectomy) the same day of surgery. The surgeon will be informed of the randomization result just before surgery by the study coordinator.

Pre-operative examinations:

History summarizing previous surgical procedures, intraocular pressure while on treatment, target pressure at the discretion of the surgeon, visual field (SITA standard 24-2), gonioscopy, and a detailed description of the optic disc / nerve fiber layer by a glaucoma specialist was performed in all subjects included.

Post-operative examinations

Visits were undertaken at 1 day, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, and 12 months.

Tests:

  • visual fields (month 12)
  • gonioscopy (month 12)
  • intraocular pressure (all visits)
  • optic disc examination (all visits, under dilation at 3 and 12 month)
  • Pachymetry (preop exam)
  • endothelial cell count (months 3 and 12)
  • Bleb morphology (month 1 and 12)
  • methodic registration of complications (all visits)

A specific CRF was designed with all variables and data required for the study which included a long list of individual potential complications

Pre-operative treatment. Prostaglandin analogues will be discontinued one week before surgery, but the rest of hypotensive drugs will be maintained until the day of surgery

Surgery. Each patient was assigned to one of the two arms (Ex-PRESS or Deep sclerectomy) the same day of surgery. The surgeon wil be informed of the randomization result just before surgery by the study coordinator.

The surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior rectus or corneal traction suture, phacoemulsification through 2.1 to 2.8 mm incision with IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application MMC 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 50 ml of saline solution, then and according to the randomization result a scleral flap (5x5 mm in the NPDS, 4x4 mm in the Ex-Press group) is dissected.

Group 1. Then the Ex-PRESS device was placed according to the manufacturer's instructions and its position in the anterior chamber was verified by the surgeon.

Group 2. Deep sclerectomy (NPDS) was performed by dissecting a Deep scleral flap (4x4 mm) and peeling the trabeculo-descement membrane. A Esnoper (AJL, Vitoria, Spain) device was positioned under the external scleral flap and fixated with a 10/0 nylon suture.

Suture Nylon 10/00 suture was used to place four or five stitches in the Ex-Press group and 2 stitches in the NPDS group. Then a hermetic conjunctival suture was performed at the limbus with 10/0 nylon.

Post-operative treatment. All patients instilled Moxifloxacin Antibiotic every 6 hours for 1 week, Dexamethasone (every 2 hours for 1 month, every 4-6 hours on the second month and gradually tapered on the third month according to surgeon's instructions). Atropine was also used at the discretion of the surgeon when clinical finds recommended its use.

Suture lysis or gonio-punture were indicated and performed at the discretion of the surgeon, and they were always registered in the CRF.

Subconjunctival injections of anti-fibrotic agents and/or bleb needling were allowed and performed at the discretion of the surgeon.

DATA ANALYSIS Variables will be checked for normality using the Shapiro-Wilk test. The mean and standard deviation is going to be used to describe normally distributed variables which will be compared between independent groups using the Student t test. Variables that are found to be not normally distributed will be described by median and quartiles, and their comparison between independent groups wil be performed using the Mann-Whitney U test.

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension

Keywords

  • Glaucoma
  • Ocular hypertension
  • Filtration surgery
  • Trabeculectomy with Ex-PRESS
  • Non penetrating deep sclerectomy
  • Phacoemulsification
  • Combined surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of open-angle glaucoma. Points a, b and c will be required:

    1. Glaucomatous visual field. Defined as the field presenting at least:

      • A group of 3 or more points with p \< 5% in the pattern deviation map AND
      • One of them with a p \< 1% in the pattern deviation map AND
      • Repeated in at least 2 VF.
    2. Glaucomatous optic nerve. Defined as the optic nerve observed in color photographs presenting:

      • Thinning of the neuroretinal rim that can be demonstrated by an alteration in the ISNT rule.
      • Presence of a notch "or"
      • Presence of papillary splinter hemorrhage "or"
      • Presence of a nerve fiber layer defect "or"
      • Cup to disc (C/D) ratio asymmetry > 0.3 that cannot be explained by asymmetry in the optic disc size "or"
      • C/D ratio > 0.8 that cannot be explained by a large optic disc size
    3. III or IV angle in Shaffer classification
  2. Disease poorly controlled with medical treatment and/or laser at the discretion of the ophthalmologist (progression, higher than targeted pressure, poor compliance...)
  3. Cataract with visual acuity between 0,1 (20/200) and 0.8 (20/25)

Exclusion criteria

Exclusion Criteria:

  1. Inflammatory, neovasular, closed-angle, normotensive glaucoma secondary to corticoids, or any type of glaucoma with advanced degree of functional lesion (Mean Defect \< -20 dB)
  2. Previous glaucoma surgery
  3. Previous intraocular ocular surgery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
98 participants (actual)

Study arms

  • Active comparator
    Filtration surgery with Express

    Filtration surgery with Ex-PRESS + cataract extraction (Cataract surgery and IOL implantation)

    Procedure: Filtration surgery with Ex-PRESS · Procedure: Cataract extraction

  • Active comparator
    Non penetrating surgery

    - Filtration surgery with Non penetrating deep sclerectomy + cataract extraction (Cataract surgery and IOL implantation)

    Procedure: Non penetrating deep sclerectomy · Procedure: Cataract extraction

Interventions

  • ProcedureFiltration surgery with Ex-PRESS

    Filtration surgery with Ex-PRESS

  • ProcedureNon penetrating deep sclerectomy

    Non penetrating deep sclerectomy

  • ProcedureCataract extraction

    Cataract surgery and IOL implantation

06

What researchers measure

Primary outcomes

  1. Intraocular pressure

    mmHg

    Time frame: Up to 12 months

Secondary outcomes

  1. Success rate at IOP <18

    percentage of patients with \< of 18 mmHg in intraocular pressure

    Time frame: Up to 12 months

  2. Number of participants with adverse events assesed by questionare in case report file.

    Bullet list of complications to check for at each study visit from the date of randomization upt to 12 months List of complications in Case report file: Avascular bleb Bleb fibrosis Choroidal effusion Corectopia Corneal edema Corneal erosion Cystoid macular edema Descemet folds Epiretinal membrane Fibrin IOL Foreign body sensation Hematic tyndall Hypotony \> 1 month Hypotony Maculopathy Iris incarceration Iris synechiae Lamellar macular hole Posterior capsule opacity Postoperative shunt closure Postoperative uveitis Seidel (early) Shallow anterior chamber Subconjunctival hemorrhage Tenon Cist Transient hypotony VA declined \> 2 Snellen lines Vitreous in anterior chamber

    Time frame: Up to 12 months

  3. Number of hypotensive medications needed

    Number of drugs prescribed by investigator to keep IOP under target from the date of randomization up to 12 months

    Time frame: Up to 12 months

07

Study locations

1 site
  • Institut Catala de Retina
    Barcelona, 08017, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jun 2015 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2011
First posted
Jun 28, 2017
Start
Feb 2012
Primary completionActual
Jun 2015
CompletionActual
Jun 2016
Last update
Jun 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03201354
Lead sponsor
Institut Catala de Retina
Collaborators
Gregorio Marañón Hospital, Clinica Universidad de Navarra, Universidad de Navarra, Hospital Vall d'Hebron, Hospital Universitario Ramon y Cajal, Hospital San Eloy, Hospital del Mar
Responsible party
Sponsor
First posted
Jun 28, 2017
Start date
Feb 2012
Primary completion
Jun 2015
Completion
Jun 2016
Last update
Jun 28, 2017

Study contacts

Alfonso Antón, MD, PhD
principal investigator · Institut Catala de Retina

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion